Bowen Hanes & Co. Inc. Has $123.90 Million Stock Position in Eli Lilly and Company $LLY

Bowen Hanes & Co. Inc. cut its position in Eli Lilly and Company (NYSE:LLY) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,294 shares of the company’s stock after selling 2,016 shares during the quarter. Eli Lilly and Company comprises approximately 3.1% of Bowen Hanes & Co. Inc.’s holdings, making the stock its 5th biggest position. Bowen Hanes & Co. Inc.’s holdings in Eli Lilly and Company were worth $123,904,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Cidel Asset Management Inc. grew its position in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after acquiring an additional 5,591 shares during the last quarter. Spire Wealth Management grew its position in Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after acquiring an additional 592 shares during the last quarter. Coldstream Capital Management Inc. grew its position in Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC grew its position in Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after acquiring an additional 5,595 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,081.34 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,149.10. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business’s 50 day moving average price is $965.78 and its two-hundred day moving average price is $1,011.48. The firm has a market cap of $1.02 trillion, a PE ratio of 38.41, a price-to-earnings-growth ratio of 1.16 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the firm earned $3.34 earnings per share. The company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its pipeline with a $1.9 billion partnership with Ascidian Therapeutics focused on kidney disease treatments, reinforcing management’s strategy of using obesity cash flow to fund acquisitions and diversify beyond GLP-1 drugs. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Lilly reported encouraging clinical updates for its obesity and immunology pipeline, including progress in the TRIUMPH-1 retatrutide study and a pediatric ulcerative colitis trial for mirikizumab, both of which support longer-term growth expectations. Lilly’s TRIUMPH-1 Retatrutide Trial Reaches Key Milestone in Obesity Drug Race Lilly’s Pediatric Ulcerative Colitis Trial Marks Key Step for Mirikizumab Growth
• Positive Sentiment: Coverage news also remained favorable, with CVS Caremark and other major pharmacy benefit managers broadening access to Lilly’s obesity portfolio, which should improve prescription volume for Zepbound and Foundayo. Eli Lilly Wins Back CVS Health, Reverting Novo’s Advantage

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. CICC Research boosted their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $1,300.00 to $1,330.00 in a report on Thursday, May 21st. Guggenheim restated a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Weiss Ratings cut Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.